DNMT3A and acute lymphoblastic leukemia: Furthermore, BIRC5 was also heterogeneously increased in DNMT3A-wildtype T-ALL specimens after CRISPR/Cas9 targeting for DNMT3A (Figure 6I), and DEX + RUX treatment reduced BIRC5 protein levels (Figure 6J).